Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration
The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried o...
Gespeichert in:
| Veröffentlicht in: | Journal of Cancer 2021-01, Vol.12 (2), p.417-427 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 427 |
|---|---|
| container_issue | 2 |
| container_start_page | 417 |
| container_title | Journal of Cancer |
| container_volume | 12 |
| creator | Wu, Fengpeng Zhou, Chaoxi Wu, Bingyuan Zhang, Xiaoxiao Wang, Kanghua Wang, Jun Xiao, Linlin Wang, Guiying |
| description | The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried out on the auxiliary use of other drugs with Fu-nCRT. However, due to specific challenges and the potential opportunities that coexist in this field, a more reasonable approach to the mode of treatment remains to be explored. In this review, we have summarized the results of the studies on the combination of Fu-nCRT with cytotoxic drugs, anti-tumor angiogenesis, and anti-EGFR agents, as well as the status of the application of immune checkpoint inhibitors in the neoadjuvant therapy of LARC patients. |
| doi_str_mv | 10.7150/jca.48337 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7739002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475086246</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-600a094c2f741e616b23fbd3561292f630b8becc0890c39c75bc94984f14fc713</originalsourceid><addsrcrecordid>eNpdkc1q3DAUhUVpaEKaRV-gCLppF071Z8nqojCYJi0MDfSHLoUsSxkNHsmV7IBfJM8bTTINabSRLufT4R4OAG8wOhe4Rh-3Rp-zhlLxApzghopKcs5ePnkfg7Oct6gcKolg9BU4ppRKzGhzAm5Xfe_DNVz12_lGhynDKcKLYY4pjkvyO19UW3U62x5-t1EfMNhu7C4m3fs4bWzS4wJdTHAdjR6GpbgVyJQvP6yZ9ADb_ZQ-wVWAV-PkY4B_Ypo2C4wO_rTJxznDNobs--K111-DI6eHbM8O9yn4ffHlV_u1Wl9dfmtX68owRKeKI6SRZIY4wbDlmHeEuq6nNcdEEscp6prOGoMaiQyVRtSdkUw2zGHmjMD0FHx-8B3nbmd7Y8OU9KDGklynRUXt1f9K8Bt1HW-UEFQiRIrB-4NBin9nmye189nYYdDBllSKMFGjhhPGC_ruGbqNcwolniK1bCguafbUhwfKpJhzsu5xGYzUvnBVClf3hRf27dPtH8l_9dI7Ezio0A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598316006</pqid></control><display><type>article</type><title>Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Wu, Fengpeng ; Zhou, Chaoxi ; Wu, Bingyuan ; Zhang, Xiaoxiao ; Wang, Kanghua ; Wang, Jun ; Xiao, Linlin ; Wang, Guiying</creator><creatorcontrib>Wu, Fengpeng ; Zhou, Chaoxi ; Wu, Bingyuan ; Zhang, Xiaoxiao ; Wang, Kanghua ; Wang, Jun ; Xiao, Linlin ; Wang, Guiying</creatorcontrib><description>The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried out on the auxiliary use of other drugs with Fu-nCRT. However, due to specific challenges and the potential opportunities that coexist in this field, a more reasonable approach to the mode of treatment remains to be explored. In this review, we have summarized the results of the studies on the combination of Fu-nCRT with cytotoxic drugs, anti-tumor angiogenesis, and anti-EGFR agents, as well as the status of the application of immune checkpoint inhibitors in the neoadjuvant therapy of LARC patients.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.48337</identifier><identifier>PMID: 33391438</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher Pty Ltd</publisher><subject>Adjuvants ; Cancer therapies ; Cell division ; Chemotherapy ; Colorectal cancer ; Cytotoxicity ; Drug dosages ; Growth factors ; Medical prognosis ; Meta-analysis ; Metastasis ; Radiation therapy ; Review</subject><ispartof>Journal of Cancer, 2021-01, Vol.12 (2), p.417-427</ispartof><rights>The author(s).</rights><rights>2021. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-600a094c2f741e616b23fbd3561292f630b8becc0890c39c75bc94984f14fc713</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739002/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739002/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,27922,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33391438$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Fengpeng</creatorcontrib><creatorcontrib>Zhou, Chaoxi</creatorcontrib><creatorcontrib>Wu, Bingyuan</creatorcontrib><creatorcontrib>Zhang, Xiaoxiao</creatorcontrib><creatorcontrib>Wang, Kanghua</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><creatorcontrib>Xiao, Linlin</creatorcontrib><creatorcontrib>Wang, Guiying</creatorcontrib><title>Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried out on the auxiliary use of other drugs with Fu-nCRT. However, due to specific challenges and the potential opportunities that coexist in this field, a more reasonable approach to the mode of treatment remains to be explored. In this review, we have summarized the results of the studies on the combination of Fu-nCRT with cytotoxic drugs, anti-tumor angiogenesis, and anti-EGFR agents, as well as the status of the application of immune checkpoint inhibitors in the neoadjuvant therapy of LARC patients.</description><subject>Adjuvants</subject><subject>Cancer therapies</subject><subject>Cell division</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Cytotoxicity</subject><subject>Drug dosages</subject><subject>Growth factors</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Metastasis</subject><subject>Radiation therapy</subject><subject>Review</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkc1q3DAUhUVpaEKaRV-gCLppF071Z8nqojCYJi0MDfSHLoUsSxkNHsmV7IBfJM8bTTINabSRLufT4R4OAG8wOhe4Rh-3Rp-zhlLxApzghopKcs5ePnkfg7Oct6gcKolg9BU4ppRKzGhzAm5Xfe_DNVz12_lGhynDKcKLYY4pjkvyO19UW3U62x5-t1EfMNhu7C4m3fs4bWzS4wJdTHAdjR6GpbgVyJQvP6yZ9ADb_ZQ-wVWAV-PkY4B_Ypo2C4wO_rTJxznDNobs--K111-DI6eHbM8O9yn4ffHlV_u1Wl9dfmtX68owRKeKI6SRZIY4wbDlmHeEuq6nNcdEEscp6prOGoMaiQyVRtSdkUw2zGHmjMD0FHx-8B3nbmd7Y8OU9KDGklynRUXt1f9K8Bt1HW-UEFQiRIrB-4NBin9nmye189nYYdDBllSKMFGjhhPGC_ruGbqNcwolniK1bCguafbUhwfKpJhzsu5xGYzUvnBVClf3hRf27dPtH8l_9dI7Ezio0A</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Wu, Fengpeng</creator><creator>Zhou, Chaoxi</creator><creator>Wu, Bingyuan</creator><creator>Zhang, Xiaoxiao</creator><creator>Wang, Kanghua</creator><creator>Wang, Jun</creator><creator>Xiao, Linlin</creator><creator>Wang, Guiying</creator><general>Ivyspring International Publisher Pty Ltd</general><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210101</creationdate><title>Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration</title><author>Wu, Fengpeng ; Zhou, Chaoxi ; Wu, Bingyuan ; Zhang, Xiaoxiao ; Wang, Kanghua ; Wang, Jun ; Xiao, Linlin ; Wang, Guiying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-600a094c2f741e616b23fbd3561292f630b8becc0890c39c75bc94984f14fc713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adjuvants</topic><topic>Cancer therapies</topic><topic>Cell division</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Cytotoxicity</topic><topic>Drug dosages</topic><topic>Growth factors</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Metastasis</topic><topic>Radiation therapy</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Fengpeng</creatorcontrib><creatorcontrib>Zhou, Chaoxi</creatorcontrib><creatorcontrib>Wu, Bingyuan</creatorcontrib><creatorcontrib>Zhang, Xiaoxiao</creatorcontrib><creatorcontrib>Wang, Kanghua</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><creatorcontrib>Xiao, Linlin</creatorcontrib><creatorcontrib>Wang, Guiying</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Fengpeng</au><au>Zhou, Chaoxi</au><au>Wu, Bingyuan</au><au>Zhang, Xiaoxiao</au><au>Wang, Kanghua</au><au>Wang, Jun</au><au>Xiao, Linlin</au><au>Wang, Guiying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>12</volume><issue>2</issue><spage>417</spage><epage>427</epage><pages>417-427</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried out on the auxiliary use of other drugs with Fu-nCRT. However, due to specific challenges and the potential opportunities that coexist in this field, a more reasonable approach to the mode of treatment remains to be explored. In this review, we have summarized the results of the studies on the combination of Fu-nCRT with cytotoxic drugs, anti-tumor angiogenesis, and anti-EGFR agents, as well as the status of the application of immune checkpoint inhibitors in the neoadjuvant therapy of LARC patients.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher Pty Ltd</pub><pmid>33391438</pmid><doi>10.7150/jca.48337</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1837-9664 |
| ispartof | Journal of Cancer, 2021-01, Vol.12 (2), p.417-427 |
| issn | 1837-9664 1837-9664 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7739002 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Adjuvants Cancer therapies Cell division Chemotherapy Colorectal cancer Cytotoxicity Drug dosages Growth factors Medical prognosis Meta-analysis Metastasis Radiation therapy Review |
| title | Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T14%3A51%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adding%20Adjuvants%20to%20Fluoropyrimidine-based%20Neoadjuvant%20Chemoradiotherapy%20for%20Locally%20Advanced%20Rectal%20Cancer:%20An%20Option%20Worthy%20of%20Serious%20Consideration&rft.jtitle=Journal%20of%20Cancer&rft.au=Wu,%20Fengpeng&rft.date=2021-01-01&rft.volume=12&rft.issue=2&rft.spage=417&rft.epage=427&rft.pages=417-427&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.48337&rft_dat=%3Cproquest_pubme%3E2475086246%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2598316006&rft_id=info:pmid/33391438&rfr_iscdi=true |